Inve US ▾

Summit Therapeutics (SMMT) earnings

Summit Therapeutics Inc.· Health Care

Results to
Jun 2026
Latest analysed call
Jun 2026 (Q2 FY26)
Balance sheet to
Dec 2025

Company research is public. Sign in to keep your own companies, notes and cases.

Summit Therapeutics earnings: last reported Thu, 23 Jul 2026, for the quarter ended Jun 2026.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
RevenueUnavailable—Quarterly, as filedQuarter to Jun 2026Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Operating marginUnavailable—Operating profit / revenueQuarter to Jun 2026Not in the filed figures for the quarter to jun 2026. No older figure is substituted.
Net profit-216 $ million—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.

Source: Inve data from filed results (SEC filings) · to Jun 2026

Guidance

What management said, and what became of it

7 of 7 judged targets kept · 7 open · verdicts reflect calls analysed to Jun 2026.

Summit Therapeutics Inc. management guidance track record on Inve: 14 targets tracked across analysed earnings calls (7 achieved, 0 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
HARMONi-3 non-squamous cohort enrollment completionComplete non-squamous cohort enrollment in the second half of 2026Dec 2025Jun 2026:our global Phase III HARMONi-3 all-comers trial evaluating ivonescimab with chemo in frontline non-small cell lung cancer has completed enrollment in both the squamous and non-squamous cohorts.
Call transcript, Jun 2026 · no direct link		Achieved
GSK B7-H3 ADC collaboration trial initiation (first patient dosed)Expected to begin dosing patients in mid-2026Dec 2025Jun 2026:Our GSK collaboration evaluating ivonescimab in multiple solid tumor settings in combination with their B7-H3 ADC, is expected to enroll its first patient later this quarter.
Call transcript, Jun 2026 · no direct link		Delayed
Arcus Biosciences (casdatifan) collaboration initial dataInitial data expected to be generated by mid-2027Jun 2026Jun 2026:We expect initial data from this collaboration to be generated by mid next year.
Call transcript, Jun 2026 · no direct link		New

Source: Inve Guidance Tracker for Summit Therapeutics Inc. · to Jun 2026

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of Summit Therapeutics Inc.'s 14 targets are still open. See which are on track and which have gone quiet. The 3 above are the free sample; 11 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. US Pro opens 100 a month: first month free, no card.
See the full record

Price

$15.47 −0.51% · −$0.08

Last close Oct 23, 2026 · US · USD · Source: Inve

Performance −19.3% 1Y

$15.0$20.0$25.0Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Jun 2026 (Q2 FY26) — 23 Jul 2026

1Y: $19.16 on 22 Oct 2025 → $15.47. High $26.38 (21 Apr 2026), low $12.43 (20 Aug 2026).

Previous close
$15.55
52-week range
$12.43 – $26.38
One year
−17.49%

Overview

Symbol
SMMT
Exchange
US
Currency
USD

Your own record

Start an Inve Case for Summit Therapeutics Inc.

Free account. Everything above stays public.

Write why you follow Summit Therapeutics Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other US companies filed under S

All 278 companies under S

US companies A–Z · Earnings calls · US earnings-call directory · US sector analysis · What management promised, and delivered